Recipharm subsidiary files infectious disease drug application in
European markets


16 December 2013

Drug product developed through partnership with Astimex Pharma.

RPH Pharmaceuticals AB a subsidiary of Recipharm AB announces the filing of an application for an infectious disease drug product in a range of European countries. The product has been developed through a partnership with Swedish pharmaceutical company, Astimex Pharma AB, which is set to market the product in the Nordic market.

As a "first in class generic", the product, owned by RPH Pharmaceuticals, will be licensed to third parties for distribution in markets where Astimex presently is not represented.

In addition to the filed application, Astimex and RPH Pharmaceuticals have expanded their collaboration with another manufacturing and development project in which the drug target is another first in class generic approved for use in most of the North European markets.

The collaboration represent joint investments where Recipharm builds a registration dossier, whilst Astimex takes full responsibility for sales and distribution in the Swedish market and RPH Pharmaceuticals can out-license sales and distribution rights in other markets.

Johan Åkerblom, Business Development Manager, RPH Pharmaceuticals commented: “We are delighted that the collaboration with Astimex is proving to be so successful for both our companies. Indeed, we are greatly excited by the pace at which drug products are being developed and licensing, sales and distribution arrangements are being set in place. Furthermore, the sales potential for the collaboration products looks very promising with the infectious disease target being one clear example of this.”

Notes to editors

About RPH Pharmaceuticals

RPH Pharmaceuticals AB is a wholly owned subsidiary of Recipharm AB responsible for the management of the intellectual property held by the group.

About Recipharm AB

Recipharm AB is a leading contract development and manufacturing organization (CDMO) based in Sweden employing some 1700 employees. The Company operates development and manufacturing facilities in Sweden, France, the UK, Germany and Spain and is headquartered near Stockholm. Recipharm supplies the global pharmaceuticals market with hundreds of different products in multiple dosage forms that include solid dose, granulates and powders, sterile liquids and lyophilisates, semi solids, beta-lactams, hormones, oral liquids, sprays and dry powder inhalers.

The Development Services arm offer services from straight forward manufacture of clinical trial material through to more complex product development and formulation. From our pharmaceutical development centre we can work on a variety of technologies, including sterile products. Formulation development, analytical method development and stability studies are all core activities. For more information visit: www.recipharm.com

About Astimex Pharma

Astimex Pharma is a Swedish pharmaceutical company founded in 2007. The company markets and distributes pharmaceuticals, medical devices and merchandise to the pharmacy market in Sweden, Denmark and Finland. Astimex has it´s headquarter near Stockholm.

Astimex ambition is to play an important role in the Nordic market by delivering products that are unique, effective, safe, environment friendly, user friendly and cost effective. Astimex range is selected to improve the health and quality of life for consumers and patients.

The majority of revenues come from products sold under licensing or distribution agreements. Astimex collaborating with leading contract development and manufacturing organizations. For more information visit: www.astimex.se

Contact information

Astimex Pharma AB:
Åsa Lintzén
Tel: +46 8-51 51 15 35

RPH Pharmaceuticals AB:
Carl-Johan Spak
Tel:+46 8-60 25 313

For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: E-mail: t.jervis@defacto.com or a.heeley@defacto.com
Tel: +44 (0) 207 861 3019/3043